SCHEMBL1820277

SCHEMBL1820277

CONC(=O)C(C)(Oc1ccc(OC)cc1)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.47
PPARA Q07869 1/20 0.47
KMT2A Q03164 3/20 0.45
MEN1 O00255 2/20 0.45
ALDH1A1 P00352 4/20 0.43
KIF11 P52732 4/20 0.43
CES2 O00748 1/20 0.42
CES1 P23141 1/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
GAA P10253 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
HTT P42858 1/20 0.41
MAPT P10636 1/20 0.41
KCNN4 O15554 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
LMNA P02545 1/20 0.40
ALOX15 P16050 1/20 0.40
APEX1 P27695 1/20 0.40
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1818707 0.92 PPARA (0.47) PPARGPPARAKMT2AMEN1ALDH1A1
SCHEMBL1819286 0.90 PPARG (0.46) PPARGPPARAKMT2AMEN1ALDH1A1
SCHEMBL1821690 0.90 PPARG (0.46) PPARGPPARAKMT2AMEN1ALDH1A1
SCHEMBL1819391 0.87 NPC1 (0.43) PPARGPPARAKMT2AMEN1CES2
SCHEMBL1820711 0.80 MCL1 (0.43) PPARGPPARAKMT2AMEN1ALDH1A1
SCHEMBL1821618 0.80 PPARA (0.44) PPARGPPARAKMT2AMEN1ALDH1A1
SCHEMBL1819151 0.80 CNR1 (0.41) PPARGPPARAKMT2AMEN1ALDH1A1
SCHEMBL1824421 0.78 BCHE (0.47) PPARGPPARAKMT2AMEN1ALDH1A1
SCHEMBL1818640 0.76 HDAC3 (0.58) PPARGPPARANPC1RAB9AKCNN4
SCHEMBL1819039 0.76 PPARA (0.46) PPARGPPARAKMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947712-B2 Antiarthritic agents; asthma; chronic obstructive pulminary diosrders; atherosclerosis; vision defects; hepatitis; central nervous system disorders; cardiovascular disorders; wound healing agents; restenosis; cirrhosis; multiple sclerosis; glomerulonephritis; graft versus host disease; antidiabetic agent WYETH LLC (US) 2011-05-24 US disclosed
US-20080269213-A1 8-Hydroxyquinoline compounds and methods thereof WYETH (US) 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269213-A1 8-Hydroxyquinoline compounds and methods thereof MMP8, MMP26, MMP9 PPARG 1416/4885PPARA 2595/4885KMT2A 4052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.